COPD
Red Flags — act before continuing history
| Red flag | Why dangerous | Action |
|---|---|---|
| SpO₂ <88% at rest or RR >25/min, unable to complete sentences | Severe or life-threatening exacerbation: type 1 or type 2 respiratory failure. Uncontrolled O₂ can precipitate CO₂ retention in chronic hypercapnia. | 999 immediately |
| Haemoptysis (frank blood in sputum) | Lung cancer in a smoker until proven otherwise. Also: TB, pulmonary embolism, bronchiectasis. Even one episode warrants urgent chest X-ray and 2WW referral. | Urgent CXR + 2WW |
| Confusion or drowsiness in a patient with COPD | CO₂ retention (type 2 respiratory failure) — PaCO₂ rising to narcotic levels. Do not give high-flow oxygen. Requires ABG, NIV, and hospital admission urgently. | 999 — NIV urgently |
| Sudden onset pleuritic chest pain and dyspnoea | Spontaneous pneumothorax — more common in COPD with bullae. Tension pneumothorax is immediately life-threatening. PE must also be excluded. | 999 — CXR urgently |
| Cyanosis (central blue discolouration of lips/tongue) | PaO₂ <6–7 kPa — severe hypoxaemia. Oxygen must be titrated carefully to 88–92% in known COPD to avoid hypercapnic respiratory failure. | 999 — titrated O₂ |
| Significant unintentional weight loss ≥5% in 6 months + smoking history | Lung cancer — the commonest cancer causing death in the UK. COPD is an independent risk factor. Low threshold for 2WW especially with persistent cough, hoarseness, or haemoptysis. | CXR + 2WW urgent referral |
| New or markedly worsened ankle oedema + raised JVP | Cor pulmonale with decompensation. Indicates severe chronic hypoxaemia with right heart failure. Requires LTOT assessment and hospital input for haemodynamic stability. | Same-day assessment |
Safeguarding Considerations — Consider in Every Consultation
🏠 Domestic Abuse / Intimate Partner Violence
- Chronic stress from abusive relationships worsens breathlessness and reduces adherence to treatment
- Smoking as a coping mechanism for abuse — cessation is harder without addressing root cause
- Patient may be unable to attend exercise programmes or pulmonary rehab due to controlling partner
- Ask sensitively if seen alone: "Is everything OK at home — do you feel safe?"
- Refer to IDVA if DASH screen positive; document safeguarding concerns in records
👴 Older Adults / Carer-related Concern
- Carer may be withholding inhalers, mismanaging oxygen, or neglecting exacerbation symptoms
- Financial exploitation may prevent purchase of nebuliser equipment, batteries, or prescription charges
- Patient may minimise symptoms to avoid burdening carer or family — ask directly about help at home
- Advance care planning may be driven by family rather than patient's own wishes
- Refer to Adult Safeguarding if neglect or exploitation suspected; involve community COPD nurse
🧒 Children in the Household
- Passive smoking exposure to children in the household — parental continued smoking worsens children's lung health and increases asthma risk
- Parent with severe COPD exacerbation requiring 999 — who is caring for children?
- Parental breathlessness may limit ability to participate actively in children's schooling, activities, or care
- Discuss smoke-free household as a health message for the whole family, not just the patient
💊 Self-Harm / Medication Misuse Risk
- Depression affects 40% of COPD patients — screen actively (PHQ-9); undertreated depression worsens breathlessness perception and reduces adherence
- Nebuliser misuse: over-using salbutamol nebuliser at home (bypassing self-management plan) may indicate uncontrolled disease or psychological dependence
- Corticosteroid prescribing — prolonged courses can cause psychological disturbance including agitation; review dose and duration
- End-stage COPD patients may express a wish to die due to unrelieved suffering — explore this with compassion; involve palliative care team
🚬 Tobacco Dependency and Shame
Smoking is pharmacologically addictive; guilt and shame about continued smoking are major barriers to disclosure and help-seeking. Patients often self-blame and disengage if this is handled punitively.
"Stopping smoking is the hardest thing to do and nicotine is incredibly addictive — can you tell me how you feel about it right now?"If still smoking: offer combination pharmacotherapy (varenicline + NRT). Referral to Stop Smoking Service doubles quit rates. Non-judgmental framing is essential.
🏚️ Housing and Fuel Poverty
Cold, damp housing triggers COPD exacerbations directly — temperature drops of ≥5°C increase exacerbation risk. Mould exposure worsens respiratory inflammation. Fuel poverty means patients heat themselves, not their homes.
"Can you tell me about your home — is it easy to keep warm in winter, or is heating a worry for you?"Refer to social prescribing for energy bill support, Warm Homes Scheme, and housing improvement grants. Document housing conditions in records.
💼 Employment and Functional Loss
COPD commonly affects working-age adults in manual occupations. MRC ≥3 often renders patients unable to continue their trade. Loss of occupational identity and income causes profound grief and secondary depression.
"Has your breathing started to affect your work or the things you used to be able to do? How has that been for you?"Industrial disease compensation may be available for occupational COPD. Refer to occupational health and welfare benefits advice. Pulmonary rehabilitation improves functional capacity.
😰 Anxiety and Breathlessness Cycle
Breathlessness triggers anxiety; anxiety amplifies breathlessness perception — a vicious cycle. Patients may avoid all exertion out of fear, worsening deconditioning. Panic attacks can mimic acute exacerbations, leading to inappropriate A&E attendances.
"Sometimes breathlessness can make people feel very frightened or panicky — do you find that happens to you?"Breathing retraining (Buteyko, diaphragmatic), pulmonary rehab, and NHS Talking Therapies referral all reduce the anxiety-breathlessness cycle. Benzodiazepines worsen respiratory drive in COPD.
🤝 Social Isolation and Activity Avoidance
Breathlessness causes embarrassment in social settings — eating in public, walking slowly, needing to stop. Patients progressively withdraw, losing social networks and worsening depression and inactivity.
"Has breathlessness stopped you doing things you used to enjoy, or meant you're spending more time at home?"Pulmonary rehabilitation provides supervised exercise and social contact. Social prescribing to walking groups, breathe-easy groups, or COPD peer support networks reduces isolation.
🏥 Advance Care Planning Avoidance
End-stage COPD often involves more suffering than terminal malignancy yet receives far less palliative input. Patients and families often do not understand the trajectory. GPs frequently defer ACP conversations, leaving patients without documented wishes at times of crisis.
"Some of my patients with more serious breathing problems like to talk about what they'd want if things got much worse — is that something you've thought about?"Introduce ACP early (GOLD 3–4). Document DNACPR, ceiling of care, and preferred place of death. Refer to palliative care for symptom management and family support.
- Asking smoking history without calculating pack-years
- Failing to ask about exacerbation frequency in the last 12 months
- Diagnosing COPD without mentioning spirometry
- Not asking about inhaler technique before stepping up therapy
- Missing haemoptysis → not triggering 2WW pathway
- Failing to screen for anxiety or depression despite prominent breathlessness
999 or Same-Day Hospital
Call 999 / A&E now- Severe exacerbationSpO₂ <88%, RR >25, cyanosis, confusion, unable to complete sentences, accessory muscle use
- Type 2 respiratory failureDrowsy, CO₂ retention, PaCO₂ rising — requires ABG and NIV
- Tension pneumothoraxSudden onset severe dyspnoea, tracheal deviation, absent breath sounds unilaterally
- Massive haemoptysisFrank blood ≥200 mL or haemodynamic instability
- Cor pulmonale decompensationSudden severe ankle oedema, raised JVP, SpO₂ deteriorating acutely
Same-Day GP / Urgent Referral
Days to 2 weeks- Moderate exacerbation — no hospital criteria metIncreased breathlessness + purulent sputum; SpO₂ ≥88%; not confused; treat in community
- Haemoptysis — not massiveStreaks of blood in sputum; requires same-day CXR and 2WW referral if smoking history
- New or worsening cor pulmonaleProgressive ankle oedema, elevated JVP without acute respiratory failure
- Rapid functional declineMRC score has deteriorated ≥2 grades in 3 months; exclude lung cancer
- First spirometry confirmationClinical COPD diagnosis needs confirmation; arrange within 2–4 weeks if symptomatic
- Post-exacerbation review overduePatient had exacerbation >6 weeks ago without formal review — urgent medicine reconciliation and care plan update
Manage in Primary Care
GP practice- Stable COPD — annual reviewSpO₂ stable, no exacerbations, review adherence and technique, update self-management plan
- Mild exacerbation at homeMild increase in breathlessness, non-purulent sputum, SpO₂ unchanged — patient has self-management plan and rescue pack
- Inhaler step-up reviewNot achieving CAT <10 or MRC improvement — adjust therapy using NICE NG115 algorithm
- Smoking cessation reviewStill smoking — motivational review and pharmacotherapy optimisation
- Pulmonary rehab referralMRC ≥3 — refer to pulmonary rehabilitation programme (8–12 weeks)
- Vaccination catch-upOffer flu, pneumococcal, COVID, and RSV vaccinations at every opportunity
- Not asking about SpO₂ or respiratory rate in an acute exacerbation
- Admitting all exacerbations to hospital without using community management criteria
- Missing haemoptysis → failure to trigger 2WW
- Failing to give a rescue antibiotic and steroid pack to frequent exacerbators
- Not distinguishing moderate exacerbation (community) from severe (hospital)
- Not checking SpO₂ in any breathless patient
- Attributing clubbing to COPD — it is NOT a COPD feature
- Failing to note cor pulmonale signs (oedema, raised JVP) in severe COPD
- Counting wheeze as absent breath sounds or vice versa
- Missing tracheal deviation as a pneumothorax sign
- Diagnosing COPD on peak flow — spirometry is mandatory
- Not ordering eosinophil count before adding ICS
- Not mentioning CXR for new COPD presentation
- Failing to request AAT in patient under 45
- Ordering ABG without SpO₂ trigger or LTOT indication
"Your breathing test shows that your airways are narrower than they should be — not in a way that comes and goes like asthma, but in a way that's been changing gradually over many years. This is called COPD — chronic obstructive pulmonary disease. Think of the airways in your lungs like a network of tubes. In COPD, those tubes have become permanently narrowed and the air sacs at the end have lost some of their springiness. That means when you breathe out, air gets trapped, and your lungs have to work much harder. The good news is this is not cancer, and the right treatment can make a real difference to how you feel day-to-day — but I want to be honest with you: we can't reverse the damage that's already there, which is why stopping smoking, if you haven't already, is the single most important thing we can do together."
"It's just my age — everyone gets breathless as they get older."
"You're absolutely right that we notice more breathlessness as we get older — but the kind of breathlessness that's been stopping you from walking up the hill is different. Your breathing test shows a specific, measurable change in the airways that goes beyond normal ageing, and importantly, there are treatments that can help you feel much better."
"I stopped smoking three years ago, so the damage must have stopped."
"Stopping smoking is one of the best things you've ever done for your lungs, and it genuinely has slowed the progression down — but unfortunately, some of the changes that already happened over the years remain. What we can do now is treat those changes to reduce your symptoms and prevent your lungs from getting worse as quickly as they might otherwise."
COPD (confirmed)
Post-BD FEV₁/FVC <0.70 + compatible clinical history. GOLD stage by FEV₁ % predicted. Diagnose in primary care; specialist input for GOLD 3–4 or if diagnosis uncertain.
Chronic bronchitis
Productive cough ≥3 months × 2 consecutive years. May coexist with obstructive spirometry. Managed in primary care with smoking cessation and mucolytics.
Asthma-COPD Overlap (ACO)
Fixed obstruction + significant reversibility (>400 mL) or eosinophilia or atopy. ICS indicated from outset. Can be diagnosed clinically; respiratory opinion helpful in complex cases.
Bronchiectasis
Daily productive cough, frequent chest infections, purulent sputum. Crackles not wheeze. CT confirms dilated bronchi. Spirometry may show mixed or obstructive pattern. Physiotherapy and prophylactic antibiotics needed.
Pulmonary fibrosis (IPF/ILD)
Progressive breathlessness, bibasal fine crackles, clubbing (unlike COPD), restrictive spirometry. HRCT ground-glass opacities. Requires respiratory specialist and MDT. Do not treat as COPD.
Pulmonary hypertension
Breathlessness, exertional syncope, right heart failure signs. May complicate severe COPD (secondary) or exist independently. Echo is the screening tool; right heart catheterisation for confirmation. Refer cardiology/respiratory.
Lung cancer
Haemoptysis, weight loss, clubbing, or persistent new symptoms in a smoker. CXR alone misses up to 20% of cases — CT required. 2WW referral mandatory. COPD increases lung cancer risk 5-fold regardless of smoking cessation.
Pulmonary embolism
Sudden onset dyspnoea, pleuritic chest pain, tachycardia in a COPD patient may be PE — not just exacerbation. COPD is a PE risk factor. Wells score + D-dimer or CTPA; do not attribute all acute breathlessness to COPD.
- Using "FEV₁/FVC ratio" without explaining what that means to the patient
- Not addressing the hidden lung cancer fear
- Giving an entirely negative prognosis without mentioning what can be done
- Failing to check patient understanding after explanation
- Not acknowledging patient's emotional response to diagnosis
- Referring to respiratory without including spirometry results
- Deferring all treatment to the specialist instead of managing in primary care
- Not mentioning pulmonary rehabilitation when MRC ≥3
- Prescribing LTOT without two stable-state ABGs
- Missing 2WW trigger for haemoptysis in a smoker
Validate — name their expectation
The commonest COPD expectation in primary care is antibiotics for every exacerbation, or a cure ("just fix my lungs"). Naming this expectation — even when you cannot meet it — demonstrates active listening and prevents the patient feeling dismissed. Validation is not agreement; it is acknowledgment.
"I completely understand you want to feel better and get back to doing the things you enjoy — that's exactly what we're aiming for together."Explain — share your clinical reasoning
Patients deserve to understand why their expectation may or may not be the right approach. Explaining the evidence — that antibiotics add little when the picture is not bacterial (though NG114 weighs several factors, not purulence alone), that maintenance inhalers work better than reliever-only treatment — empowers patients to be partners rather than recipients of care.
"I want to explain why the inhaler I'm suggesting works differently to what you may have tried before — and why the evidence says it's likely to make a real difference to your breathing."Negotiate — offer something today
Never let a patient leave with nothing agreed. Even if the main expectation cannot be met (cannot "cure" COPD), there is always something that can be offered today: a rescue pack, a new inhaler, a pulmonary rehab referral, a smoking cessation referral, or a written self-management plan.
"I'd like to start you on a new inhaler today — and I'll also give you a written plan so you know exactly what to do if your breathing gets worse, including when to start the rescue antibiotics and steroids we can prescribe for you to keep at home."The only intervention proven to slow the natural history of COPD — reduces FEV₁ decline from ~60 mL/year in current smokers to ~30 mL/year in ex-smokers (close to normal). Also reduces lung cancer risk, cardiovascular risk, and exacerbation frequency.
Combination NRT (patch + fast-acting) or varenicline (most effective single agent, 25% quit rate at 12 months). Refer to NHS Stop Smoking Service — doubles quit rates. E-cigarettes: not recommended in NICE NG115 but NICE TA886 supports use as cessation aid. Set a quit date; address triggers.
Structured supervised aerobic exercise + education programme. Reduces peripheral muscle deconditioning (major contributor to breathlessness in COPD), breaks the anxiety-breathlessness cycle, improves respiratory muscle strength, and provides peer support.
Refer via local community pulmonary rehab programme. Recommend within 4 weeks of a hospital admission for exacerbation. For those who cannot attend in person, virtual PR is available. Typical programme: 2–3 sessions/week × 8–12 weeks. Benefits last up to 12 months.
Viral respiratory infections (influenza, RSV, SARS-CoV-2) are the most common triggers of COPD exacerbations. Vaccination reduces the frequency and severity of these triggers directly.
Annual influenza vaccine (ideally October/November). Pneumococcal (PPV23 + PCV15/20): reduces hospitalisation for pneumococcal pneumonia in COPD. COVID booster per current JCVI schedule. RSV vaccine (Abrysvo or mRESVIA) for age ≥75 or immunocompromised. Offer all at this consultation.
Low BMI (<20) in COPD is an independent predictor of mortality — worse than FEV₁ alone. Malnutrition impairs respiratory muscle function, immune response, and recovery from exacerbation. Conversely, obesity worsens breathlessness and increases OSA risk.
If underweight: refer to dietitian; consider nutritional supplements (Fortisip/Ensure); address food poverty. If overweight: weight reduction improves exercise tolerance and reduces co-morbid OSA. Avoid energy-dense, gas-producing foods that exacerbate bloating and diaphragm compression.
Pursed-lip breathing reduces RR and dynamic hyperinflation by creating back-pressure that keeps airways open during exhalation. Active cycle of breathing technique (ACBT) clears secretions without bronchospasm. Diaphragmatic breathing reduces use of accessory muscles.
Teach pursed-lip breathing in consultation. Refer to physiotherapy for ACBT if productive cough. Breathing retraining for anxious patients reduces hyperventilation component. Flutter/Acapella oscillating devices for bronchiectasis co-morbidity.
Continued occupational or domestic exposure to dust, fumes, biomass, or cold air accelerates FEV₁ decline regardless of optimal pharmacotherapy. Cold air is a direct bronchoconstrictor. Damp housing promotes mould, a potent airway allergen.
Advise: wear a scarf over mouth in cold weather; avoid peak traffic hours for outdoor exercise; use extractor fans when cooking; check heating adequacy — refer to social prescribing for Warm Homes Scheme or Energy Company Obligation (ECO) grants. Remove pets if sensitised.
All symptomatic COPD (CAT ≥10 or MRC ≥2): add LAMA as first maintenance inhaler
- SABA (salbutamol 100–200 µg PRN) for all patients as reliever
- SAMA (ipratropium 20 µg QDS) if SABA not sufficient or not tolerated
- LAMA first-line maintenance: tiotropium 18 µg OD or umeclidinium 62.5 µg OD or aclidinium 322 µg BD
- Check inhaler technique and device suitability before prescribing
- All patients: written self-management plan + rescue pack prescription
Still symptomatic on LAMA or if asthmatic features / eos ≥300:
- Non-asthmatic + still breathless: LABA+LAMA combination (e.g. umeclidinium/vilanterol — Anoro Ellipta; or indacaterol/glycopyrronium — Ultibro)
- Asthmatic features (wheezy, reversible, atopy) OR eos ≥300: LABA+ICS preferred (e.g. salmeterol/fluticasone — Seretide; or budesonide/formoterol — Symbicort)
- LABA MUST NOT be prescribed as monotherapy in COPD
- ICS MUST NOT be prescribed as monotherapy in COPD
Frequent exacerbators (≥2/year) despite dual therapy:
- Triple inhalers: fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) OD; or budesonide/glycopyrronium/formoterol (Breztri Aerosphere) BD
- IMPACT trial: triple therapy reduced moderate/severe exacerbations by 25% vs LAMA alone
- Check eosinophil count — benefit greatest at eos ≥300; consider ICS withdrawal if eos <100
- Monitor for ICS side effects: pneumonia risk, oral candidiasis, osteoporosis
- Roflumilast (PDE4 inhibitor): FEV₁ <50%, chronic bronchitis phenotype, ≥2 exacerbations/year despite triple therapy. Reduces exacerbations by ~17%. GI side effects (diarrhoea, nausea, weight loss). Usually initiated by specialist.
- Prophylactic azithromycin 250 mg OD or 500 mg 3×/week: ≥2 hospitalising exacerbations/year despite optimal therapy. Must check: QTc ≤450ms; no NTM on sputum culture; hearing test. Annual surveillance required. NTM risk: never in patients with high TB risk.
- LTOT: PaO₂ ≤7.3 kPa on two occasions ≥3 weeks apart (stable state). Must be used ≥15h/day to gain mortality benefit (MRC LTOT trial). Active smoking is a relative contraindication (fire risk).
- Asthma-COPD Overlap (ACO): ICS essential from outset — never withhold ICS in ACO. Follow asthma guidelines in addition to COPD.
- Mucolytics — carbocisteine 375 mg TDS: NICE NG115 recommends for persistent productive cough not responsive to bronchodilators alone. Reduces exacerbation frequency (PEACE trial).
- Theophylline: Third-line bronchodilator; narrow therapeutic index; drug interactions (ciprofloxacin, clarithromycin double levels). Levels 10–20 mg/L. Rarely used now with dual/triple bronchodilators available.
- Corticosteroid courses (exacerbation): Prednisolone 30 mg OD × 5 days (NICE NG115). Not longer. Not higher dose. Do NOT prescribe longer courses — no additional benefit and significant harm.
- Inhaled corticosteroids — ICS withdrawal: Consider in patients with <2 exacerbations/year, eos <300 cells/µL and stable on dual LABA+LAMA. Use caution — exacerbation risk increases transiently.
Select patient characteristics — COPD maintenance inhaler recommendation appears below
"This is your reliever inhaler — use it when you're breathless, before exercise, or if you wake short of breath. If you find yourself using it several times every day, that usually means we need to look at adding a regular inhaler to help prevent the breathlessness in the first place — let me know if that's happening."
SCA pearl: Increasing SABA use is a marker of uncontrolled COPD — prescribing more SABA without stepping up maintenance therapy = Domain 1 deduction. Link SABA frequency to management review.
"This is a once-a-day maintenance inhaler that works by relaxing the muscles around your airways, keeping them more open throughout the day and night. You won't feel it working like a reliever inhaler — it works in the background. Keep using your blue reliever if you get acutely breathless. Please let me know if you notice any difficulty passing water or eye pain."
SCA pearl: LAMA is the first-line maintenance inhaler in COPD — not LABA+ICS. Prescribing LABA+ICS as first-line in non-asthmatic COPD is a common SCA error and represents over-prescribing ICS without indication.
"This inhaler contains two different medicines that work together — one relaxes the small muscles in your airways and the other opens them up in a complementary way. Together they work better than either one alone. It's a once-daily inhaler and you should use it at the same time every morning."
SCA pearl: FLAME trial (NEJM 2016) showed LABA+LAMA was superior to LABA+ICS for exacerbation prevention in non-asthmatic COPD. In SCA, prescribing LABA+ICS before checking for asthmatic features = domain deduction.
"This inhaler contains a steroid and a bronchodilator — the steroid reduces inflammation in your airways, and the bronchodilator keeps them more open. It's important to rinse your mouth out with water after every puff — spit the water out, don't swallow it — to prevent a mouth infection. If you develop a fever or a much more productive cough, please let me know quickly."
SCA pearl: ICS in COPD increases pneumonia risk — this must be mentioned in counselling. Failure to mention the pneumonia risk and the mouth-rinsing requirement = SCA deduction in the counselling domain.
"This inhaler has three medicines in it working together — it's the strongest inhaler combination we have for COPD. It's really important to rinse your mouth out with water after each dose. One important side effect to know about is that the steroid component can slightly increase the risk of getting a chest infection — so please come and see me quickly if you develop a fever or notice your sputum change colour."
SCA pearl: Triple therapy is the most commonly cited step in COPD SCA cases because it is the most complex decision point. Examiners look for: eosinophil count checked, pneumonia counselling given, and mouth-rinsing advised. All three are required for full marks.
"I'm giving you a supply of antibiotics and a short steroid course to keep at home. The plan is: if your breathing gets much worse, or your phlegm becomes much thicker or turns yellow or green, start both medicines that same day — you don't need to wait to see me first. But I do need to know if you've used them — please call the surgery so we can arrange a follow-up and check you're recovering well."
SCA pearl: Prescribing a rescue pack without a written self-management plan that specifies when to use it = incomplete safety-netting. In SCA, the rescue pack and the plan must be mentioned together.
Driving
COPD does not automatically require DVLA notification. However, if breathlessness causes sudden incapacity, or if the patient is on LTOT or has recurrent hypercapnic episodes causing drowsiness, DVLA notification is required under the DVLA A Glance guide for respiratory conditions.
Home oxygen cylinders transported in a vehicle must be stored safely and not within 1.5m of an ignition source. Active smoking with home O₂ is a fire risk requiring explicit safety counselling — this is a prescribing responsibility.
If cor pulmonale causes severe exercise limitation or confusion, fitness to drive must be actively assessed and documented at annual review.
"There are no automatic restrictions on driving with COPD, but because you're using oxygen, I'd like to go through a couple of important safety rules with you — and if things get significantly worse, we would need to notify the DVLA."Work and Employment
COPD in manual occupations (construction, mining, agriculture) frequently renders patients unable to continue their trade by GOLD 2–3. Loss of occupational identity, income, and social structure from work causes profound grief and secondary depression.
Industrial disease compensation (Industrial Injuries Disablement Benefit — IIDB) is available for occupational COPD. GPs should document occupational exposures clearly and refer to occupational health where relevant. A detailed occupational history may be medico-legally important.
Severe COPD qualifies as a disability under the Equality Act 2010 — employers must make reasonable adjustments (lighter duties, seated work, proximity to welfare facilities). GP letters supporting workplace adjustment requests carry significant weight.
"Has the breathing been affecting your ability to work? I can write a letter to support adjustments at work — and we should talk about any benefit entitlements you might not know about."Relationships and Intimacy
Breathlessness on exertion directly impairs sexual activity — a topic patients rarely raise spontaneously but frequently experience as a significant quality-of-life loss. Without proactive GP enquiry, this issue goes unaddressed for years.
Partners often become primary carers as COPD progresses — a role change that strains relationships. Carer burnout is common. Carers have their own health needs and should be directed to Carers UK and local carer support services.
Practical advice: choosing positions that minimise exertion, using SABA 15 minutes before activity, timing activity for when breathlessness is least (mid-morning for most patients), reduces avoidance behaviour.
"Some people find that breathlessness affects intimacy as well — is that something that's been an issue for you? There are some practical suggestions that genuinely help and I'd like to go through them if you're comfortable."Anxiety, Depression and the Breathlessness Cycle
Up to 40% of COPD patients have clinically significant depression; up to 50% have anxiety. Both are frequently underdiagnosed and undertreated. Breathlessness triggers panic; panic worsens breathlessness — a self-perpetuating cycle with measurable physiological consequences (hyperventilation, increased RR, dynamic hyperinflation).
Benzodiazepines are not first-line for anxiety in COPD — they suppress respiratory drive. SSRIs (sertraline, citalopram) are safer and evidence-supported. Pulmonary rehabilitation significantly improves both anxiety and depression scores in COPD patients.
Screen with PHQ-9 and GAD-7 at every annual review. Do not dismiss anxiety as "understandable given the breathlessness" — it is a treatable comorbidity that worsens clinical outcomes if left untreated. NHS Talking Therapies referral is highly appropriate.
"Living with breathlessness every day is genuinely hard, and it's very common for that to affect your mood. How has it been affecting how you're feeling in yourself — your mood, your enjoyment of life?"Independence and Social Participation
Progressive loss of independence — inability to clean, shop, walk, or socialise — causes profound grief and identity loss in COPD patients. Breathlessness causes social withdrawal and increasing dependence on others, which compounds depression and reduces motivation for self-management.
Community COPD nurse, social prescribing to Breathe Easy peer support groups, and voluntary sector organisations (Asthma + Lung UK) provide social contact and condition-specific support. For housebound patients, community physiotherapy and virtual pulmonary rehab are alternatives to centre-based programmes.
Care plan for GOLD 3–4 COPD should include an assessment of care needs and referral to Adult Social Care where relevant. Home adaptations (stair lift, wet room, grab rails) can maintain independence significantly longer than pharmacotherapy alone.
"Has your breathing stopped you from doing things you used to enjoy, or meant you're spending more time at home on your own? There are some services and support groups I'd like to tell you about."Advance Care Planning and End of Life
COPD is the third most common cause of death in the UK, yet receives a fraction of the palliative care input given to cancer patients with equivalent or worse prognosis. The trajectory — interspersed with survivable and non-survivable acute exacerbations — means ACP conversations are frequently deferred until a crisis that prevents meaningful discussion.
DNACPR decisions, ceiling of care (NIV vs invasive ventilation), and preferred place of care should be documented by GOLD 3 — not at GOLD 4 crisis point. Most patients welcome the conversation when introduced sensitively at a routine review. GP-initiated ACP is both appropriate and therapeutic for the patient and family.
Opioids (low-dose oral morphine) are safe, evidence-based, and effective for refractory dyspnoea in end-stage COPD when titrated carefully. Withholding opioids out of respiratory drive concern at end of life causes unnecessary suffering and is not consistent with evidence or palliative guidelines.
"Some of my patients with more serious breathing problems find it helpful to talk about what they'd want if things got much worse — about their wishes for future treatment. Is that something you'd feel comfortable discussing today or at a future appointment?"2 Weeks — Post-exacerbation telephone review
Check recovery, medication completion (antibiotics and steroid course), SpO₂ if home monitor available. Identify any ongoing deterioration requiring face-to-face assessment or hospital referral. Confirm 6-week appointment is already booked. Blood glucose check in diabetics who took prednisolone course.
6 Weeks — Post-exacerbation formal review
NICE NG115 mandated. Full medication review including in-person inhaler technique check. Re-measure CAT or MRC score. Assess whether step-up of maintenance therapy is warranted. Consider pulmonary rehabilitation referral if not already done. Update written self-management plan. Reassess smoking status. Document exacerbation in running total for the year.
3 Months — New diagnosis review
For newly diagnosed patients only: confirm spirometry report received and reviewed, explain diagnosis and GOLD stage, assess response to first maintenance inhaler, address smoking cessation, arrange pulmonary rehabilitation referral, provide and review written self-management plan, review blood eosinophil count result and link to inhaler choice, check vaccination status, screen PHQ-9/GAD-7.
Annual COPD Review — all stable patients
Structured annual review: spirometry if suspected deterioration; CAT or MRC score; exacerbation count since last review; in-person inhaler technique check; smoking status and cessation support; vaccination status (flu, pneumococcal, COVID, RSV if ≥75); PHQ-9/GAD-7; BMI and nutrition; blood eosinophil count; SpO₂ — if <92%, arrange ABG for LTOT assessment; medication step-up or step-down decision; self-management plan update; ACP discussion if GOLD 3–4.
Triggered Review — any deterioration or concern
Rapid functional decline (MRC ↑ ≥2 in 3 months), new haemoptysis, new weight loss ≥5%, new ankle oedema, worsening SpO₂, ≥3 exacerbations in 12 months, or failure to recover from last exacerbation all mandate an unscheduled review. Each trigger requires a specific decision: step-up, 2WW referral, LTOT assessment, or specialist referral. Document trigger and action taken.
Memory rule
FEEL-FIT: FEV₁ (if clinically deteriorating) · Eosinophils (annually — guides ICS add/withdraw) · Exacerbation count (log every episode — ≥2/year = step up) · LTOT criteria (SpO₂ <92% → ABG × 2 stable) · Flu/pneumococcal/RSV vaccines · Inhaler technique (check at every visit before step-up) · Treatment response (CAT/MRC every review)
⚠ Three scenario-specific phrases — use these verbatim
Why safety-netting matters beyond clinical care
- No safety-netting or vague safety-netting ("come back if worse")
- No follow-up appointment stated or timepoint named
- No written self-management plan offered
- Failing to mention pulmonary rehabilitation when MRC ≥3
- Not addressing smoking if patient still smoking
- Prescribing ICS without advising mouth-rinsing
- No teach-back or closing question asked
- Spirometry requested or reported, diagnosis explained in plain language
- Inhaler choice matched to eosinophil count and asthmatic features
- Rescue pack prescribed with written trigger criteria
- Pulmonary rehabilitation offered to MRC ≥3 patients
- Smoking cessation offered with pharmacotherapy if still smoking
- Specific follow-up named (2 weeks, 6 weeks, annual)
- Expectation named and validated before management plan presented
- Diagnosis in plain language — analogy used, "not cancer" addressed
- Emotional response to diagnosis acknowledged empathetically
- Non-judgmental approach to smoking history throughout
- Shared decision-making — patient asked "Does this feel right for you?"
- Functional impact explicitly acknowledged and linked to treatment goals
- Safety-net specific and comprehensible to a lay person
Who you are
Derek Hartley, 64-year-old retired bricklayer. Stopped smoking three years ago after 35 years — approximately 35 pack-years. Lives alone since divorce five years ago. Gets breathless walking up the stairs at home and stopping halfway up the hill to the shops. Had two courses of antibiotics last winter for "chest infections." No formal COPD diagnosis has ever been made. No spirometry has been performed.
Hidden agenda
Derek is terrified he has lung cancer. His father died of lung cancer at age 62 and Derek has been avoiding GP attendance because he fears a cancer diagnosis. He believes "there's no point" in rehabilitation because he thinks nothing can fix what he has done to his lungs. He will not volunteer the cancer fear unless the GP asks directly about what is worrying him.
Symptoms if asked directly
- Morning cough daily — produces grey sputum, much worse in winter
- Breathless on two flights of stairs; stops halfway up the hill to the local shops
- Two chest infections last year; one the year before — both treated with antibiotics
- No haemoptysis, no weight loss, no current fever
- Occasional wheeze in cold weather or damp conditions
- No ankle swelling, no orthopnoea, no chest pain
Lifestyle + bonus details
- Stopped smoking 3 years ago — proud of this but doesn't think it "fixed" anything
- Lives alone; doesn't go out much; small garden he can no longer manage
- Eats poorly since divorce — mostly ready meals; 4 kg weight loss over 12 months (offer only if asked directly about weight)
- Drinks 3–4 cans of lager per night "to help me sleep"
- Takes ibuprofen regularly for a bad knee
- Bonus (mood — only if asked): "I don't see the point in much anymore, if I'm honest. It's not like I'm going to get better, is it?"
Resolution: Derek will accept the management plan and engage with pulmonary rehabilitation if the GP: (1) directly names and addresses the cancer fear ("based on what you've told me, this sounds like COPD rather than cancer — let's do a chest X-ray to make sure, and I'll explain the difference"); (2) acknowledges the grief of functional loss ("losing the ability to do things you used to is a real loss, and I don't want to minimise that"); (3) explains specifically why the LAMA inhaler is different from what he has used before; and (4) responds to the depression cue ("I don't see the point") with compassion and a PHQ-9 screen rather than moving on.
- SpO₂ <88% + RR >25 + accessory muscles + cyanosis
- Confusion or drowsiness → CO₂ retention / type 2 RF
- Tension pneumothorax (tracheal deviation, absent breath sounds)
- Massive haemoptysis or haemodynamic instability
- Acute cor pulmonale decompensation
- Moderate exacerbation — SpO₂ ≥88%, speaking in sentences
- Haemoptysis → CXR + 2WW same day
- New ankle oedema / cor pulmonale features
- Rapid functional decline (MRC ↑≥2 grades in 3 months)
- First diagnosis: spirometry within 2–4 weeks
- Stable COPD — annual structured review
- Mild exacerbation with self-management plan in place
- Inhaler review / step-up decision
- Pulmonary rehabilitation referral (MRC ≥3)
| Drug / Treatment | Test | Timing | Action threshold |
|---|---|---|---|
| All COPD | SpO₂; inhaler technique check | Every consultation | SpO₂ <92% × 2 stable → ABG for LTOT; poor technique → re-educate before any step-up |
| ICS / triple therapy | Oral cavity; eosinophil count; CXR if fever/worsening | Annually; at any exacerbation | Candida → nystatin; pneumonia → admit if severe; eos <300 + no exac → ICS withdrawal |
| Prednisolone (rescue or LTOT) | Blood glucose (DM); DEXA if ≥3 courses/year | After every course in DM | BG >15 → insulin review; ≥3 courses/year → alendronate + Ca/vitamin D + DEXA |
| Azithromycin prophylaxis | ECG (QTc); audiometry; LFTs; NTM sputum | Before starting; 3-monthly × 1yr; then annually | QTc >450 → don't start; NTM+ → don't start; hearing loss → stop |
| Theophylline | Serum level; ECG | 3–6 monthly; after dose changes / interacting drugs | Level >20 mg/L → toxic — reduce urgently; ciprofloxacin / macrolides double levels |
| LTOT | ABG × 2 (stable state, ≥3 weeks apart) | Before prescribing; annual review | PaO₂ ≤7.3 kPa → prescribe ≥15h/day; active smoking → fire risk counselling mandatory |
→ Post-bronchodilator spirometry is mandatory; peak flow cannot diagnose airflow obstruction
→ ICS must always be combined with LABA in COPD; monotherapy ICS is not indicated
→ NICE's gate is asthmatic features (previous asthma/atopy, higher eosinophils, FEV₁ variation ≥400ml, diurnal PEF variation ≥20%), then persisting symptoms or frequent exacerbations. GOLD trial context: eos ≥300 = greater benefit; <100 = pneumonia risk without benefit
→ Any haemoptysis in a smoker = 2WW lung cancer referral + urgent CXR; do not reassure without exclusion
→ Target SpO₂ 88–92% only; high-flow O₂ causes CO₂ retention in chronic hypercapnia
→ Non-judgmental approach; acknowledge addiction; offer pharmacotherapy; lecturing reduces engagement
→ Check technique at every review; most apparent failures are technique failures, not drug failures
→ Oral candidiasis is common and preventable; rinse-and-spit after every dose is mandatory counselling
→ Rescue pack without a written plan specifying when to start = incomplete safety-netting; NICE NG115 requires both